Skip to content

Aspen’s comparable revenue increases by 12% to R35.4 billion

September 14, 2016

Aspen’s comparable revenue increases by 12% to R35.4 billion Johannesburg – JSE Limited listed Aspen Pharmacare Holdings Limited (APN), a leading pharmaceutical company in the southern hemisphere, has announced positive results for the year ended 30 June 2016 notwithstanding economic pressures and currency weaknesses.   Stephen Saad, Aspen Group Chief Executive said, “The positive results…

Read More

Aspen’s comparable revenue increases by 12% to R35.4 billion

September 14, 2016

Aspen’s comparable revenue increases by 12% to R35.4 billion Johannesburg – JSE Limited listed Aspen Pharmacare Holdings Limited (APN), a leading pharmaceutical company in the southern hemisphere, has announced positive results for the year ended 30 June 2016 notwithstanding economic pressures and currency weaknesses.   Stephen Saad, Aspen Group Chief Executive said, “The positive results…

Read More

Aspen Joins World Thrombosis Day Campaign

September 1, 2016

Company Joins Movement as Global Contributor to Raise Awareness of  Thrombosis as an Urgent Health Problem Worldwide September 01, 2016 – Aspen, a leading global player in specialty and generic pharmaceuticals with an extensive basket of products that provide treatment for a broad spectrum of acute and chronic conditions experienced through all stages of life, today…

Read More

European Haematology Association (EHA) meeting

June 9, 2016

A forum for presenting original unpublished data and sharing ideas for haematological innovation as well as disseminating evidence-based knowledge of primary clinical relevance. 9 – 12 June Copenhagen, Denmark Visit the ISTH website here Event website not yet available

Read More

Aspen AstraZeneca Anaesthetics Portfolio Agreement

June 6, 2016

Aspen Holdings is pleased to announce that its wholly owned subsidiary, Aspen Global Incorporated (“AGI”), has signed an agreement with AstraZeneca AB and AstraZeneca UK (“AstraZeneca”) whereby AGI will acquire the exclusive rights to commercialise AstraZeneca’s global (excluding the USA) anaesthetics portfolio (“the Transaction”). AstraZeneca’s anaesthetics portfolio comprises seven established medicines, namely Diprivan (general anaesthesia),…

Read More

Heart Failure 2016 (European Society of Cardiology meeting)

May 21, 2016

The congress spotlight is ‘State of the Art’ and will consider the latest ways to make a heart failure diagnosis, predict patient outcomes, manage heart failure with drugs and devices and efficiently structure clinical services. The latest ESC Guidelines ‘For the diagnosis and treatment of acute and chronic heart failure’, written under the auspices of the…

Read More

Aspen demonstrates economic growth and specialized technologies contributions to Deputy President Cyril Ramaphosa

April 14, 2016

Port Elizabeth. JSE-listed Aspen, the largest pharmaceutical manufacturer in the southern hemisphere, earlier today hosted Deputy President Cyril Ramaphosa and Minister of Health Dr Aaron Motsoaledi at its Port Elizabeth-based flagship manufacturing site. The visit provided an opportunity to discuss Aspen’s economic growth and export contributions to South Africa, and to demonstrate its globally recognised…

Read More
Scroll To Top